- Login
- Register & Subscribe
- Sprache: EN FR DE
Research & University News
Galapagos reports data on JAK inhibitor
Tuesday 22 November 2011
Galapagos NV has become the latest company to report positive clinical data for an oral Janus kinase (JAK) inhibitor in rheumatoid arthritis, an autoimmune disease that is estimated to affect about 1% of the world’s population. Current treatments include non-steroidal anti-inflammatory drugs; methotrexate, and biologic medicines.
Location
Belgium
US to co-fund vaccine project involving European companies
Tuesday 15 November 2011
The US government is to co-fund a four-year vaccine research project that involves technology from three European companies including that from CureVac GmbH which has developed a technology for messenger RNA vaccines.
Location
Germany
Sanofi reports further positive data for alemtuzumab
Monday 14 November 2011
Sanofi SA has reported further positive data for the candidate multiple sclerosis treatment, alemtuzumab, this time from a Phase 3 trial in patients with relapsing-remitting MS who had relapsed while on therapy. The comparator was Rebif.
Location
France
Researchers describe how malaria parasite invades cells
Monday 14 November 2011
Using new screening technology, UK researchers have been able to describe how the malaria parasite, Plasmodium falciparum, invades human red blood cells. The finding was published online in Nature on 9 November 2011.
Location
United Kingdom
Phase 3 study of adjunct therapy for depression fails
Tuesday 8 November 2011
The first of four Phase 3 trials which are investigating a new compound as an adjunct therapy to antidepressants has failed to meet its primary endpoint, according to AstraZeneca Plc and Targacept Inc, the sponsors.
Location
United Kingdom
Evolva advances compound for complications of diabetes
Monday 7 November 2011
Evolva Holding SA said it has received regulatory clearance to start a Phase 2a study in Germany of a compound to treat the complications of diabetes. The compound, EV-077, is thought to have potential as a treatment for vascular events in diabetics.
Location
Switzerland
CureVac reports immune response to second cancer vaccine
Monday 7 November 2011
CureVac GmbH has reported data from an early clinical trial of a second cancer vaccine that is based on messenger RNA (mRNA). The study showed that 65% of patients with non-small cell lung cancer responded to at least one of five antigens.
Location
Germany
Phase 2b study starts for vaccine against liver cancer
Friday 4 November 2011
Transgene SA of France and Jennerex Inc of the US have announced the start of a Phase 2b study of a vaccine for patients with advanced liver cancer who have failed prior treatment with sorafenib, the only approved drug for the disease.
Location
France
Transgene to start cancer vaccine trial
Sunday 30 October 2011
Transgene SA said it expects to start recruiting patients in December for a Phase 2b study of its cancer vaccine, TG4010, in patients with advanced non-small cell lung cancer. This follows regulatory approvals in the UK and France with further approvals expected soon.
Location
France
Regorafenib 3 trial stopped after meeting primary endpoint
Wednesday 26 October 2011
A Phase 3 trial of the multi-kinase inhibitor, regorafenib, for patients with metastatic colorectal cancer has met its primary endpoint of a statistically significant improvement in overall survival, according to Onyx Pharmaceuticals Inc.
Location
United States
Select a News Category
Recent Appointments
Pascale Witz to head strategic development at Sanofi
Monday May 6 2013
Srinivas Akkaraju joins Sofinnova Ventures
Monday May 6 2013
Vicente Anido nominated to Nicox board
Monday May 6 2013
Jeremy Farrar named director of the Wellcome Trust
Monday May 6 2013
Harry Kirsch becomes CFO at Novartis
Monday May 6 2013